Haemoperitoneum as an indicator of GIST

Anticancer Drugs. 2012 Jun:23 Suppl:S10-2. doi: 10.1097/CAD.0b013e3283559fde.

Abstract

We report the case of a 62-year-old woman who presented to the emergency department with abdominal pain and distension. She was diagnosed with haemoperitoneum and a large tumour that occupied the entire left hypochondrium and attached to the posterior surface of the fundus of the stomach at the level of the greater curvature. Anatomical pathology examination identified the tumour as a gastrointestinal stromal tumour with highly malignant characteristics and the haemoperitoneum was considered to contribute to a worse prognosis because of its ability to produce a peritoneal seeding. Considering these adverse characteristics, imatinib was initiated as an adjuvant treatment, with no evidence of relapse in the follow-up.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Chemotherapy, Adjuvant
  • Female
  • Gastrointestinal Neoplasms / diagnostic imaging*
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / pathology
  • Gastrointestinal Neoplasms / surgery
  • Gastrointestinal Stromal Tumors / diagnostic imaging*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / surgery
  • Hemoperitoneum / diagnostic imaging*
  • Hemoperitoneum / drug therapy
  • Hemoperitoneum / pathology
  • Hemoperitoneum / surgery
  • Humans
  • Imatinib Mesylate
  • Middle Aged
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use
  • Rupture, Spontaneous
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate